ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

被引：0
|
作者：
Gomez-Panzani, E. [1 ]
Vinik, A. [2 ]
Wolin, E. [3 ]
Audry, H. [1 ]
机构：
[1] Ipsen, Boulogne, France
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
NEUROENDOCRINOLOGY | 2014年 / 99卷 / 3-4期
关键词：
symptom control;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K5
引用
收藏
页码：271 / 271
页数：1
相关论文
共 50 条
  • [1] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
    Duchateau, L.
    Lescrauwaet, B.
    Blot, K.
    Liyanage, N.
    Ray, D.
    Lowenthal, S. P.
    Braun, S.
    Mirakhur, B.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 194 - 194
  • [3] OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)
    Hautefeuille, V
    Walter, T.
    Do Cao, C.
    Coriat, R.
    Dominguez, S.
    Mineur, L.
    Gueguen, D.
    Houchard, A.
    Mouawad, C.
    Anota, A.
    Hammel, P.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 136 - 136
  • [4] Lanreotide Depot/Autogel (LAN) Vs. Placebo (PBO) for Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs): Subgroup Analysis of the ELECT Study
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 10 - 11
  • [5] Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Higgs, K.
    Halpin, C.
    Bolton, R.
    Frankcom, I
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 86 - 86
  • [6] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients With Carcinoid Syndrome (CS)
    Duchateau, Luc
    Lescrauwaet, Benedicte
    Blot, Koenraad
    Liyanage, Nilani
    Ray, David
    Lowenthal, Susan Pitman
    Braun, Stephan
    Mirakhur, Beloo
    [J]. PANCREAS, 2018, 47 (03) : 338 - 338
  • [9] The Sequencing of Lanreotide (LAN) After Octreotide LAR (OCT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, Wasif M.
    Parikh, Rohan C.
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Halfdanarson, Thorvardur R.
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh
    Soares, Heloisa
    [J]. PANCREAS, 2019, 48 (03) : 450 - 450
  • [10] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
12345